Icon (ICLR) Projected to Post Earnings on Wednesday

Icon (NASDAQ:ICLR) is anticipated to post its Q1 2026 results after the market closes on Wednesday, July 29th. Analysts expect Icon to post earnings of $2.55 per share and revenue of $2.0043 billion for the quarter. Parties can find conference call details on the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, June 24, 2026 at 8:00 AM ET.

Icon Stock Up 1.8%

Shares of NASDAQ:ICLR opened at $168.78 on Tuesday. The stock’s 50-day moving average price is $152.21 and its 200-day moving average price is $135.77. Icon has a 12-month low of $66.57 and a 12-month high of $203.91. The stock has a market capitalization of $12.92 billion, a P/E ratio of 30.03, a price-to-earnings-growth ratio of 8.14 and a beta of 1.22. The company has a current ratio of 1.14, a quick ratio of 1.14 and a debt-to-equity ratio of 0.31.

Institutional Trading of Icon

Several institutional investors and hedge funds have recently modified their holdings of ICLR. EFG International AG purchased a new position in shares of Icon in the 4th quarter worth approximately $27,000. Johnson Financial Group Inc. purchased a new stake in Icon in the 3rd quarter worth approximately $71,000. Quadrant Capital Group LLC acquired a new stake in shares of Icon during the 3rd quarter worth approximately $78,000. Wilmington Savings Fund Society FSB grew its stake in shares of Icon by 198.8% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 487 shares of the medical research company’s stock worth $89,000 after purchasing an additional 324 shares during the period. Finally, Geneos Wealth Management Inc. increased its holdings in shares of Icon by 11.5% during the 2nd quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock valued at $79,000 after purchasing an additional 56 shares in the last quarter. 95.61% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ICLR has been the topic of a number of analyst reports. Weiss Ratings cut Icon from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, May 29th. Barclays increased their price objective on Icon from $160.00 to $175.00 and gave the company an “equal weight” rating in a research note on Thursday, June 25th. UBS Group set a $160.00 target price on shares of Icon in a report on Wednesday, June 24th. Bank of America lifted their target price on shares of Icon from $125.00 to $150.00 and gave the stock an “underperform” rating in a research note on Thursday, June 25th. Finally, TD Cowen upped their price target on shares of Icon from $164.00 to $197.00 and gave the company a “buy” rating in a report on Thursday, June 25th. Seven analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Icon currently has a consensus rating of “Hold” and an average price target of $168.73.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.